All

CITRYLL ANNOUNCES COMPLETION OF PATIENT ENROLMENT AND DOSING IN THE REPEAT DOSING STAGE OF THE PHASE 1 TRIAL FOR THE NOVEL ANTI-INFLAMMATORY DRUG, CIT-013
31 July 2024

CITRYLL ANNOUNCES COMPLETION OF PATIENT ENROLMENT AND DOSING IN THE REPEAT DOSING STAGE OF THE PHASE 1 TRIAL FOR THE NOVEL ANTI-INFLAMMATORY DRUG, CIT-013

Citryll, a clinical-stage biotech company developing first-in-class therapeutics to treat immune-mediated inflammatory diseases, today announces the successful completion of...

Read the press release
Tubulis Receives FDA Fast Track Designation for Antibody-Drug Conjugate Candidate TUB-040 in Platinum-resistant Ovarian Cancer
27 June 2024

Tubulis Receives FDA Fast Track Designation for Antibody-Drug Conjugate Candidate TUB-040 in Platinum-resistant Ovarian Cancer

Tubulis announced today that the U.S. Food and Drug Administration (“FDA”) has granted Fast Track designation to its lead antibody-drug conjugate (ADC) TUB-040 for the...

Read more
Tubulis Doses First Patient in Phase I/IIa Trial Investigating ADC Candidate TUB-040 in Ovarian Cancer and Lung Adenocarcinoma.
20 June 2024

Tubulis Doses First Patient in Phase I/IIa Trial Investigating ADC Candidate TUB-040 in Ovarian Cancer and Lung Adenocarcinoma.

Tubulis announced today that the first patient has been treated in its first Phase I/IIa trial. The study is evaluating Tubulis’ next-generation antibody-drug conjugate (ADC)...

Read the press release
MaaT Pharma Launches a Global Offering of approximately 18 Million Euros
14 May 2024

MaaT Pharma Launches a Global Offering of approximately 18 Million Euros

MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotech company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to...

Read more
Karius Raises $100M Co-Led by Khosla Ventures, 5AM Ventures and Gilde Healthcare, to Expand Access to Advanced Genomic Diagnostics in Infectious Disease, Addressing Antimicrobial Resistance Crisis
2 May 2024

Karius Raises $100M Co-Led by Khosla Ventures, 5AM Ventures and Gilde Healthcare, to Expand Access to Advanced Genomic Diagnostics in Infectious Disease, Addressing Antimicrobial Resistance Crisis

Karius®, Inc., a world leader in genomic diagnostics for infectious disease, today announced it has secured $100 million in Series C funding. The round was co-led by Khosla...

Read more
SumUp raises $1.5 billion in debt financing
1 May 2024

SumUp raises $1.5 billion in debt financing

In a major deal that reaffirms the market’s confidence in global fintech SumUp as a company with solid revenues and foundations, and a bright future, the company raised...

Read more
TransferGo raises $10M to expand its remittance business in Asia, doubling valuation
9 April 2024

TransferGo raises $10M to expand its remittance business in Asia, doubling valuation

The U.K.-based fintech best known as a consumer platform for global remittances, has raised a $10 million growth funding round from Taiwan-based investor Taiwania Capital, with...

Read more
MaaT Pharma Presents Promising Preclinical Data at AACR for MaaT034 Aiming To Improve Patients’ Responses to Immunotherapies
8 April 2024

MaaT Pharma Presents Promising Preclinical Data at AACR for MaaT034 Aiming To Improve Patients’ Responses to Immunotherapies

MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotech company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to...

Read more
Tubulis Closes Upsized €128 Million Series B2 to Accelerate Clinical Development of Solid Tumor-Focused ADC Pipeline
25 March 2024

Tubulis Closes Upsized €128 Million Series B2 to Accelerate Clinical Development of Solid Tumor-Focused ADC Pipeline

Tubulis announced the successful completion of an upsized and oversubscribed €128 million ($138.8 million) Series B2 financing.

Read the press release